Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Eisai
Eisai
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Bayer HealthCare and Johns Hopkins University to collaborate on new ophthalmic therapies
The partners will work jointly on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
FDA grants landmark approval for Alzheimer’s treatment
LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
Regulatory
AbbVie and Eisai launch online Humira support tool service
The free-of-charge service assists patients on Humira therapy by delivering support tools to their home or other requested location
Finance
Eisai and Fuji Yakuhin sign ASEAN distribution agreement for gout therapy
Hyperuricemia is known to be associated with various diseases in the urinary system, endocrine system, metabolic system, cardio-cerebrovascular system etc., including gout
Research & Development
Eisai and Biogen announce Phase IV Alzheimer's study design
The companies will be evaluating the long-term effectiveness and safety data of Biogen's Alzheimer's therapy, Aduhelm
Regulatory
Eisai and Merck combination cancer therapy approved by FDA
The approval for this population is based on results from a Phase III Study 309/KEYNOTE-775 trial
Research & Development
Eisai makes major investments in drug creation
Platform will be established to combine Eisaid know-how with external big data and genomic data for drug innovation in neurology and oncology
Ingredients
Therapeutics: lemborexant for sleep disorders
About a third of adults suffer from the symptoms of insomnia, such as difficulty falling asleep, staying asleep or both
Subscribe now